0001209191-23-032034.txt : 20230524 0001209191-23-032034.hdr.sgml : 20230524 20230524210018 ACCESSION NUMBER: 0001209191-23-032034 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230522 FILED AS OF DATE: 20230524 DATE AS OF CHANGE: 20230524 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Binder Steven B. CENTRAL INDEX KEY: 0001712601 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50865 FILM NUMBER: 23955723 MAIL ADDRESS: STREET 1: 30930 RUSSELL RANCH ROAD STREET 2: SUITE 300 CITY: WESTLAKE VILLAGE STATE: CA ZIP: 91362 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MANNKIND CORP CENTRAL INDEX KEY: 0000899460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133607736 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 BUSINESS PHONE: 818-661-5000 MAIL ADDRESS: STREET 1: 1 CASPER STREET CITY: DANBURY STATE: CT ZIP: 06810 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-22 0 0000899460 MANNKIND CORP MNKD 0001712601 Binder Steven B. 1 CASPER STREET DANBURY CT 06810 0 1 0 0 Chief Financial Officer 0 Common Stock, $.01 Par Value 2023-05-22 4 A 0 400000 4.79 A 1113539 D Common Stock, $.01 Par Value 2023-05-22 4 F 0 227405 4.79 D 886134 D Common Stock, $.01 Par Value 2023-05-24 4 S 0 47810 4.675 D 838324 D A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Transaction occurred pursuant to Rule 10B5-1 Plan. /s/ Steven B. Binder 2023-05-24